Advances in Rheumatology最新文献

筛选
英文 中文
Commentary on "Nutritional screening and extraglandular manifestations in Sjögren disease: a cross sectional study using the controlling nutritional status score and prognostic nutritional index". 对“Sjögren疾病的营养筛查和腺外表现:使用控制营养状况评分和预后营养指数的横断面研究”的评论。
IF 2.8 4区 医学
Advances in Rheumatology Pub Date : 2026-11-02 DOI: 10.1186/s42358-026-00589-1
Dong Zheyu, Shi Jieyi
{"title":"Commentary on \"Nutritional screening and extraglandular manifestations in Sjögren disease: a cross sectional study using the controlling nutritional status score and prognostic nutritional index\".","authors":"Dong Zheyu, Shi Jieyi","doi":"10.1186/s42358-026-00589-1","DOIUrl":"10.1186/s42358-026-00589-1","url":null,"abstract":"","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"66 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13726264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149326360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of depression and anxiety among patients with Behçet's disease: a systematic review and meta-analysis. behaperet病患者抑郁和焦虑的患病率:一项系统回顾和荟萃分析
IF 2.8 4区 医学
Advances in Rheumatology Pub Date : 2026-10-29 DOI: 10.1186/s42358-026-00591-7
Golbarg Mehrpoor, Mohammad Javad Amini, Arman Shafiee, Seyed Amirhossein Salehi, Reza Samiee, Gelareh Azarinoush
{"title":"Prevalence of depression and anxiety among patients with Behçet's disease: a systematic review and meta-analysis.","authors":"Golbarg Mehrpoor, Mohammad Javad Amini, Arman Shafiee, Seyed Amirhossein Salehi, Reza Samiee, Gelareh Azarinoush","doi":"10.1186/s42358-026-00591-7","DOIUrl":"10.1186/s42358-026-00591-7","url":null,"abstract":"<p><strong>Background: </strong>Behçet's disease (BD) is a chronic multisystemic vasculitis associated with significant physical and psychological morbidity, including depression and anxiety. This systematic review and meta-analysis aimed to estimate the pooled prevalence of depression and anxiety among BD patients and to examine variations by assessment tools and geographic regions.</p><p><strong>Method: </strong>Following PRISMA guidelines, a comprehensive search of PubMed, EMBASE, and Scopus was conducted up to April 2025. Data were extracted and quality-assessed using standardized tools, and pooled prevalence rates were calculated via random-effects meta-analysis.</p><p><strong>Results: </strong>A total of 17 studies were included in the systematic review, of which 16 contributed to the meta-analysis of depression and 11 to the meta-analysis of anxiety among patients with BD. The results revealed a high pooled prevalence of depression at 47.44% (95% CI: 34.09-60.97%) and anxiety at 48.48% (95% CI: 35.40-61.67%), both with substantial heterogeneity (I² > 90%). Depression prevalence varied significantly by diagnostic instrument, with PHQ-9 and HADS reporting higher rates compared to DSM-IV and MINI. Geographic differences were marked, with Egypt showing the highest prevalence for both depression (88.83%) and anxiety (92.00%), while France reported the lowest prevalence for depression (5.00%) and Brazil reported the lowest for anxiety (29.31%). No publication bias was detected.</p><p><strong>Conclusion: </strong>The findings underscore a high burden of mental health comorbidities in BD, with pooled prevalence rates of 47.44% for depression and 48.48% for anxiety, reflecting significant psychological morbidity. Geographic disparities, suggest cultural, healthcare, or socioeconomic moderators requiring further investigation. These results advocate for integrating routine mental health screening into BD management to address unmet psychiatric needs in this population.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"66 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13721388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149301318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of fibromyalgia in Egyptian patients with systemic lupus erythematosus and its impact on health-related quality of life. 埃及系统性红斑狼疮患者纤维肌痛的患病率及其对健康相关生活质量的影响
IF 2.8 4区 医学
Advances in Rheumatology Pub Date : 2026-08-24 DOI: 10.1186/s42358-026-00571-x
Samar Tharwat, Rahma A Elziaty, Fatma Hamdy, Abdelrahman Mohamed Elsayed, Esraa A Talaat, Enas S Zahran
{"title":"Prevalence of fibromyalgia in Egyptian patients with systemic lupus erythematosus and its impact on health-related quality of life.","authors":"Samar Tharwat, Rahma A Elziaty, Fatma Hamdy, Abdelrahman Mohamed Elsayed, Esraa A Talaat, Enas S Zahran","doi":"10.1186/s42358-026-00571-x","DOIUrl":"10.1186/s42358-026-00571-x","url":null,"abstract":"<p><strong>Background: </strong>Fibromyalgia (FM) is a rheumatic disorder characterized by widespread persistent pain, hyperalgesia, and allodynia.</p><p><strong>Objectives: </strong>The aim of this study was to assess the prevalence of FM among Egyptian patients with systemic lupus erythematosus (SLE) and its effect on their health-related quality of life (HRQoL).</p><p><strong>Materials and methods: </strong>This cross-sectional analytical multicenter study was conducted on 550 Egyptian SLE patients. The patients' sociodemographic characteristics, clinical and therapeutic data, and sleeping patterns were collected. SLE disease activity index (SLEDAI) was assessed. We employed the 2016 revisions to the 2010/2011 FM diagnostic criteria to determine the presence of FM and the patients administered the Short-Form Health Survey-36 (SF-36).</p><p><strong>Results: </strong>The mean (SD) age was 32.72 (9.90) years, and 91.3% were female. Of 550 Egyptian SLE patients, 119 (21.6%) fulfilled the diagnostic criteria of FM. The FM group was statistically significantly associated with higher age (P = 0.001), body mass index (BMI) (P = 0.008), longer SLE duration (p < 0.001), and higher scores of SLEDAI (p < 0.001). Also, living alone (p < 0.001), chronic psychiatric disease (p = 0.008), chronic kidney disease (p = 0.025), and chronic hemodialysis (p = 0.042) were significantly higher among the FM group. Sleep disorders, such as snoring and sleep apnea, were more prevalent among FM patients. The average sleep hours were significantly lower among the FM group (p < 0.001). FM patients had statistically significantly lower scores across all domains of SF36.</p><p><strong>Conclusion: </strong>FM is prevalent among Egyptian SLE patients, and shows significant associations withage, BMI, SLE duration and activity, and disturbed sleep pattern and has a negative impact on their HRQoL. Therefore, early detection and treatment are recommended.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"66 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13501656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148814539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding barriers: patient experience with immune-mediated rheumatic diseases in Brazilian public health. 理解障碍:巴西公共卫生中免疫介导的风湿病患者经历
IF 2.8 4区 医学
Advances in Rheumatology Pub Date : 2026-08-19 DOI: 10.1186/s42358-026-00563-x
Helena Tupinambá, Leticia Rocha Pereira, Carla Gottgtroy, Blanca Elena Rios Gomes Bica, Ingrid Bandeira Moss, Gabriela Sadigurschi, Ewerton Alves Portela Dos Santos, Janaina Reis Xavier, Maria Cristina Caetano Kuschnir, Vitor Cardoso Doria da Gama, Thalita da Matta de Castro, Maria de Lourdes de Sousa Maia
{"title":"Understanding barriers: patient experience with immune-mediated rheumatic diseases in Brazilian public health.","authors":"Helena Tupinambá, Leticia Rocha Pereira, Carla Gottgtroy, Blanca Elena Rios Gomes Bica, Ingrid Bandeira Moss, Gabriela Sadigurschi, Ewerton Alves Portela Dos Santos, Janaina Reis Xavier, Maria Cristina Caetano Kuschnir, Vitor Cardoso Doria da Gama, Thalita da Matta de Castro, Maria de Lourdes de Sousa Maia","doi":"10.1186/s42358-026-00563-x","DOIUrl":"10.1186/s42358-026-00563-x","url":null,"abstract":"<p><strong>Background: </strong>Immune-mediated rheumatic diseases (IMRDs) encompass a wide range of rheumatological conditions that have a substantial impact on morbidity and mortality globally. Due to the diversified nature of IMRD symptoms, timely recognition of these conditions in primary care settings can be challenging. The duration between symptom onset and treatment initiation is a key factor influencing prognosis of IMRD. Therefore, this study aims to evaluate the medical journey of individuals with IMRD from symptom onset to treatment.</p><p><strong>Methods: </strong>Cross-sectional observational study based on the analysis of questionnaire responses from 1,327 patients with IMRDs at two reference centers for rheumatic disease treatment in Rio de Janeiro. Quantitative variables were compared using the Mann-Whitney or Kruskal-Wallis test, while categorical and nominal variables were analyzed using McNemar's test.</p><p><strong>Results: </strong>The median time until the first rheumatologist consultation after symptom onset was 7 months (0,5-216 months) and the median time to obtain a definitive diagnosis of IMRD was 12 months (0,5-216 months). This period was shorter for individuals with systemic lupus erythematosus (SLE), with a median of 8 months (0.5-216 months), and longer for those with psoriatic arthritis (PsA), with a median of 33 months (2-195 months). Additionally, the median time from symptom onset to specific treatment initiation was also 12 months. It was shown that consulting two or more non-rheumatologists doctors before seeing a rheumatologist significantly delayed the IMRD diagnosis (p-value < 0.001). The diagnosis of IMRD had a negative impact on emotional well-being and occupational capacity on 85.9% (n = 1,139) of participants' and 68.1% (n = 903) indicated that their work was somehow affected in a negative way. Throughout the diagnostic journey, negative feelings predominated in the period in which the diagnosis was not defined, but there was a notable shift after the confirmation of the diagnosis with an increase in positive emotions such as happiness, comfort, and well-being.</p><p><strong>Conclusions: </strong>This study provides valuable information on the challenges faced in the medical journey of patients with IMRDs, from delays in diagnosis to barriers in accessing treatment and the impact on well-being, highlighting the need for multifaceted interventions to improve the management of these complex conditions.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"66 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13753221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applicability of metabolomics in axial spondyloarthritis: a scoping review. 代谢组学在轴型脊柱炎中的适用性:范围综述。
IF 2.8 4区 医学
Advances in Rheumatology Pub Date : 2026-08-06 DOI: 10.1186/s42358-026-00562-y
Denise Maiara Silva Carneiro, Déborah Catharina Campos Siqueira, Ricardo Oliveira da Silva, Claudia Diniz Lopes Marques
{"title":"Applicability of metabolomics in axial spondyloarthritis: a scoping review.","authors":"Denise Maiara Silva Carneiro, Déborah Catharina Campos Siqueira, Ricardo Oliveira da Silva, Claudia Diniz Lopes Marques","doi":"10.1186/s42358-026-00562-y","DOIUrl":"10.1186/s42358-026-00562-y","url":null,"abstract":"<p><strong>Objective: </strong>This scoping review aims to explore the applicability of metabolomics in identifying biomarkers for early diagnosis and disease monitoring in patients with axial spondyloarthritis (axSpA).</p><p><strong>Methods: </strong>We conducted a scoping review following the PRISMA-ScR and JBI guidelines. Searches were carried out on the Web of Science, Scopus, and MEDLINE databases. After applying the eligibility criteria, 13 articles were included in the final analysis.</p><p><strong>Results: </strong>Specific metabolic signatures, mainly amino acid, fatty acid, and energy and lipid metabolism metabolites, were identified as potential tools for distinguishing axSpA patients from healthy controls and assessing treatment response.</p><p><strong>Conclusion: </strong>Metabolomics holds considerable promise for advancing the understanding of axSpA pathophysiology and facilitating biomarker discovery. However, further validation in diverse populations and methodological standardization are required before these findings can be translated into clinical practice.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"66 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13732820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of symptomatic extra-articular manifestations of rheumatoid arthritis on disease activity and patient-reported outcomes: a cross-sectional and observational study. 类风湿性关节炎的关节外症状对疾病活动性和患者报告的结果的影响:一项横断面和观察性研究
IF 2.8 4区 医学
Advances in Rheumatology Pub Date : 2026-07-25 DOI: 10.1186/s42358-026-00569-5
Ahmet Oruç, Hasan Satış, Merve Oruç, Reyhan Bilici, Abdurrahman Tufan, Mehmet Akif Öztürk
{"title":"The effect of symptomatic extra-articular manifestations of rheumatoid arthritis on disease activity and patient-reported outcomes: a cross-sectional and observational study.","authors":"Ahmet Oruç, Hasan Satış, Merve Oruç, Reyhan Bilici, Abdurrahman Tufan, Mehmet Akif Öztürk","doi":"10.1186/s42358-026-00569-5","DOIUrl":"10.1186/s42358-026-00569-5","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the joints but also has extra-articular manifestations. Extra-articular manifestations (EAMs) in RA encompass a wide range of clinical findings that may significantly affect patients' quality of life. This study aimed to compare daily life, social function, and work productivity between RA patients with and without EAMs. In this study, we aimed to determine the differences in daily life, social life, and work between patients with and without EAM.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This cross-sectional and observational study included 402 RA patients (2010 ACR-EULAR). EAM was defined as systemic symptoms and organ involvement occurring outside of the joint findings caused by RA. The presence of EAM was grouped as symptomatic/asymptomatic. Patients were evaluated once during the study period in an outpatient setting. Patients completed the Health Assessment Questionnaire (HAQ), Short Form-36 (SF-36), and Work Productivity and Activity Impairment: General Health (WPAI: GH) forms under clinician observation. Continuous variables were compared using the Mann-Whitney U test and Independent Samples T-test, while Fisher's exact test or chi-square test was used for categorical variables. The significance level was set at 5% (p &lt; 0.05).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The study included 402 patients. 325 (80.8%) were female, with a median (IQR) age of 56 (47-64.25) and a mean±standard deviation (SD) disease duration of 9.7 ± 8.6 years. EAM was present in 200 patients. Patients were classified as having symptomatic EAM (sEAM) (n = 81), asymptomatic EAM (asEAM) (n = 119), and no EAM (n = 202). The median age was 60 (54.5-67), and the median age at diagnosis was 49 (39.5-58) in the sEAM group, which had the highest values (p:&lt;0.001 and p:0.003, respectively). Peripheral neuropathy detected in 24 (29.6%) patients was the most common symptomatic EAM, while keratoconjunctivitis sicca detected in 44 (36.9%) patients was the most common asymptomatic EAM. In sEAM patients, HAQ mean ± SD was 0.92 ± 0.73, while in non-EAM patients it was 0.68 ± 0.65, p = 0.021. In SF-36 results, physical function, social function, role physical, vitality, and mental health were statistically significantly lower in patients with sEAM compared to other groups. The percentage of working patients was higher at 28.2% in those without EAM, p:0.010. Absenteeism, mean ± SD, was higher in the sEAM group at 12.8 ± 28.1, p: 0.037, and activity impairment was also higher in sEAMs at mean ± SD 44.2 ± 29.1, p:0.025.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Regardless of RA disease activity, patients with sEAM experience negative impacts on both their daily and social lives as well as their work life. Symptomatic EAMs are associated with significant impairment in quality of life and work productivity, independent of traditional disease activity measures. Clinicians should therefore systemat","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"66 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13689068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149239937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Self-esteem as a determinant of sexual function in systemic lupus erythematosus patients: a cross-sectional study. 自尊作为系统性红斑狼疮患者性功能的决定因素:一项横断面研究。
IF 2.8 4区 医学
Advances in Rheumatology Pub Date : 2026-07-25 DOI: 10.1186/s42358-026-00570-y
Daniela Marengo-Rodríguez, María Espinosa-León, Monserrat Ibarra-Velasco-Siles, Paola Vázquez-Cárdenas, Erik Cimé-Aké, Jonathan Campos-Guzmán, Ana Barrera-Vargas, Javier Merayo-Chalico
{"title":"Self-esteem as a determinant of sexual function in systemic lupus erythematosus patients: a cross-sectional study.","authors":"Daniela Marengo-Rodríguez, María Espinosa-León, Monserrat Ibarra-Velasco-Siles, Paola Vázquez-Cárdenas, Erik Cimé-Aké, Jonathan Campos-Guzmán, Ana Barrera-Vargas, Javier Merayo-Chalico","doi":"10.1186/s42358-026-00570-y","DOIUrl":"10.1186/s42358-026-00570-y","url":null,"abstract":"<p><strong>Background: </strong>The correlation between self-esteem and sexual function in systemic lupus erythematosus (SLE) patients remains unexplored. The objective was to assess the association between body self-esteem, global self-esteem, and sexual function in patients with SLE.</p><p><strong>Methods: </strong>A cross-sectional study was conducted at a tertiary care center. We included patients aged 18 and older who met the EULAR/ACR criteria for SLE. Body self-esteem was measured using the Body Self-Esteem Scale (BSES), while global self-esteem was assessed with the Rosenberg Self-Esteem Scale (RSE). Sexual function was evaluated using the Changes in Sexual Functioning Questionnaire Short-Form questionnaire (CSFQ-14). Sexual dysfunction (SD) was defined as a total CSFQ-14 score of less than 41 points for women and less than 47 points for men. We assessed disease activity using the SLEDAI-2 K, and damage accrual with the SLICC damage index.</p><p><strong>Results: </strong>A total of 280 patients were included, the majority of whom were female (88.6%). The median age was 39 years (IQR 31 to 49). The median SLEDAI-2 K score was 2 (IQR 0 to 4), and the SLICC damage index was 0 (IQR 0 to 1). A total of 147 patients (52.5%) were classified as having SD. The BSES score showed a significant correlation with the total CSFQ-14 score (rho = 0.364, p < 0.001). Similarly, the RSE subcomponents, self-competence (rho = 0.262, p < 0.001) and self-liking (rho = 0.274, p < 0.001) showed both a significant positive correlation with the total CSFQ-14 score. Patients with SD compared to those without SD had significantly lower BSES scores, lower self-competence scores and lower self-liking scores. Female sex (OR 2.6, 95% CI 1.2 to 6.0, p = 0.026), lower leukocyte count (OR 1.2, 95% CI 1.0 to 1.3, p = 0.046), and lower BSES score (OR 1.9, 95% CI 1.8 to 2.1, p < 0.001) were independent risk factors for sexual dysfunction.</p><p><strong>Conclusions: </strong>This is the first study to evaluate self-esteem as a determinant of sexual function in SLE patients. Given the significant impact of self-esteem on sexual dysfunction, its relationship should be assessed during rheumatology evaluations.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"66 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13689005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149239942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of SGLT2 inhibitors on gout-related and cardiometabolic outcomes in patients with type 2 diabetes mellitus: a scoping review. SGLT2抑制剂对2型糖尿病患者痛风相关和心脏代谢结局的影响:一项范围综述
IF 2.8 4区 医学
Advances in Rheumatology Pub Date : 2026-07-24 DOI: 10.1186/s42358-026-00564-w
Henrique Pereira Sampaio, Barbara Casarin Henrique-Sanches, Carlos Antonio Negrato
{"title":"Effects of SGLT2 inhibitors on gout-related and cardiometabolic outcomes in patients with type 2 diabetes mellitus: a scoping review.","authors":"Henrique Pereira Sampaio, Barbara Casarin Henrique-Sanches, Carlos Antonio Negrato","doi":"10.1186/s42358-026-00564-w","DOIUrl":"https://doi.org/10.1186/s42358-026-00564-w","url":null,"abstract":"<p><strong>Background: </strong>This review aimed to map the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on gout-related and cardiometabolic outcomes in patients with type 2 diabetes mellitus (T2DM) and gout.</p><p><strong>Methods: </strong>A scoping review was conducted following the Joanna Briggs Institute methodology and the PRISMA-ScR checklist. Searches were performed in PubMed, EMBASE, Scopus, Web of Science, LILACS/BVS, and gray literature sources. Eligible studies included patients with T2DM and gout treated with SGLT2i, assessing outcomes such as mortality, gout flares, serum uric acid (SUA) levels, emergency care visits, and hospitalizations due to gout. The PRISMA-ScR checklist is provided in Additional file 1, and the full search strategy in Additional file 2.</p><p><strong>Results: </strong>Of 282 articles initially identified, 22 met the inclusion criteria. Most studies were retrospective cohort studies (n = 12) or post hoc analyses (n = 8). Only three studies evaluated patients with both T2DM and gout exclusively. The main findings included reductions in SUA levels (n = 8), incidence of gout (n = 12), gout flares (n = 8), initiation of urate-lowering therapy or colchicine (n = 8), and gout-related emergency care or hospital visits (n = 1). Reductions in all-cause (n = 5) and cardiovascular (CV) mortality (n = 4) were also reported. Across the included studies, SGLT2i were frequently associated with favorable effects on the analyzed outcomes.</p><p><strong>Conclusion: </strong>SGLT2i appears to be associated with multiple favorable effects in patients with T2DM and gout, including urate-lowering effects, reduced gout flares, and lower mortality (all-cause and CV-related). Although limited by the small number of studies focusing specifically on this population, these findings support the potential therapeutic relevance of SGLT2i in patients with coexisting T2DM and gout, contributing to the management of both conditions and the reduction of CV-related events associated with them.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"66 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13632354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic performance of FIB-4 in detecting advanced liver fibrosis in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis using methotrexate. FIB-4在类风湿关节炎、银屑病关节炎和银屑病患者甲氨蝶呤检测晚期肝纤维化中的诊断价值
IF 2.8 4区 医学
Advances in Rheumatology Pub Date : 2026-07-24 DOI: 10.1186/s42358-026-00567-7
Fernanda Luiza Schumacher Furlan, Patricia Martin, Alcindo Pissaia Junior, Claudia Alexandra Pontes Ivantes, Marcia Olandoski, Adriane Reichert Faria, Adriano Reinaldo Timm, Jhony Maciel de Oliveira, Giuliano Camati Dourado, Lana Bassi Ferdinando, Rebeca Rebouças Pereira, Beatriz Gallo Teixeira, Raphaela Suzin Marini Munaretto, Odery Ramos Junior
{"title":"Diagnostic performance of FIB-4 in detecting advanced liver fibrosis in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis using methotrexate.","authors":"Fernanda Luiza Schumacher Furlan, Patricia Martin, Alcindo Pissaia Junior, Claudia Alexandra Pontes Ivantes, Marcia Olandoski, Adriane Reichert Faria, Adriano Reinaldo Timm, Jhony Maciel de Oliveira, Giuliano Camati Dourado, Lana Bassi Ferdinando, Rebeca Rebouças Pereira, Beatriz Gallo Teixeira, Raphaela Suzin Marini Munaretto, Odery Ramos Junior","doi":"10.1186/s42358-026-00567-7","DOIUrl":"10.1186/s42358-026-00567-7","url":null,"abstract":"<p><strong>Background: </strong>Methotrexate is a first-line therapy for rheumatoid arthritis, psoriatic arthritis, and psoriasis, but its long-term use has been associated with hepatic fibrosis, highlighting the need for effective screening strategies. In this context, and considering the limitations of liver biopsy as well as the high cost and limited availability of elastography, the FIB-4 score has emerged as the most widely used noninvasive screening tool. This multicenter cross-sectional study evaluated patients followed at specialized Rheumatology and Dermatology centers to assess the accuracy of FIB-4 in predicting advanced hepatic fibrosis in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis undergoing chronic methotrexate therapy. The specific objectives were to identify optimal cutoff values for FIB-4 in this population and factors associated with advanced fibrosis.</p><p><strong>Methods: </strong>Medical records, interviews, and physical examinations were used to collect demographic, clinical, laboratory, lifestyle, and treatment data, calculate age-adjusted FIB-4 scores, and assess disease activity using validated indices. Liver fibrosis and steatosis were evaluated by vibration-controlled transient elastography, and FIB-4 performance for detecting advanced fibrosis was analysed using age-stratified Receiver Operating Characteristic curves and multivariable logistic regression.</p><p><strong>Results: </strong>A total of 172 patients were included, predominantly women, with a mean age of 58 years; rheumatoid arthritis was the most common underlying disease. Advanced fibrosis was identified by elastography in 11%. FIB-4 values increased progressively with fibrosis stage, and Receiver Operating Characteristic curve analysis identified a cutoff of 1.62 - a threshold not previously reported for methotrexate-treated patients. This cutoff demonstrated better performance in individuals younger than 65 years (Area Under the Curve = 0.68 versus 0.64 in those aged 65 years or older) and showed particular utility for ruling out advanced fibrosis. In multivariable analysis, a high-risk FIB-4 category, obesity, diabetes mellitus, and advanced hepatic steatosis were independently associated with advanced fibrosis, whereas inflammatory disease activity and cumulative methotrexate dose were not.</p><p><strong>Conclusions: </strong>FIB-4 is an accessible and potentially useful tool for ruling out advanced hepatic fibrosis in methotrexate-treated patients younger than 65 years, demonstrating reasonable performance in this population. Advanced fibrosis is primarily driven by metabolic factors rather than methotrexate exposure or inflammatory disease activity.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"66 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13681781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Muscle morphology changes over 1-year in patients with rheumatoid arthritis: a prospective cohort study using muscle ultrasound. 类风湿关节炎患者肌肉形态变化超过1年:一项使用肌肉超声的前瞻性队列研究。
IF 2.8 4区 医学
Advances in Rheumatology Pub Date : 2026-07-21 DOI: 10.1186/s42358-026-00529-z
Leonardo Peterson Dos Santos, Rafaela Cavalheiro do Esíprito Santo, Émerson Pena, Stephanie Pilotti, Daniel Nóbrega Moraes, André Luiz Silveira Mallmann, Lucas Denardi Dória, Gabriel Eduardo Grave, Vanessa Hax, Nicole Pamplona Bueno de Andrade, Claiton Viegas Brenol, Odirlei André Monticielo, Rafael Mendonça da Silva Chakr, Ricardo Machado Xavier
{"title":"Muscle morphology changes over 1-year in patients with rheumatoid arthritis: a prospective cohort study using muscle ultrasound.","authors":"Leonardo Peterson Dos Santos, Rafaela Cavalheiro do Esíprito Santo, Émerson Pena, Stephanie Pilotti, Daniel Nóbrega Moraes, André Luiz Silveira Mallmann, Lucas Denardi Dória, Gabriel Eduardo Grave, Vanessa Hax, Nicole Pamplona Bueno de Andrade, Claiton Viegas Brenol, Odirlei André Monticielo, Rafael Mendonça da Silva Chakr, Ricardo Machado Xavier","doi":"10.1186/s42358-026-00529-z","DOIUrl":"10.1186/s42358-026-00529-z","url":null,"abstract":"<p><strong>Background: </strong>Low muscle mass is associated with physical disability in rheumatoid arthritis (RA), highlighting the need for regular muscle assessment. Muscle ultrasound (MU) is a promising tool for evaluating muscle morphology, however, longitudinal studies in RA are lacking. This study aimed to evaluate changes in quadriceps muscle thickness and pennation angle using MU and identify predictors of these changes.</p><p><strong>Methods: </strong>This prospective observational cohort included women and men with RA. Muscle thickness and pennation angles of the rectus femoris (RF), vastus intermedius (VI), and vastus lateralis (VL) were assessed using MU. Disease activity was measured using the 28-joint Disease Activity Score based on C-reactive protein (DAS28-CRP), muscle strength by the handgrip test, physical performance by Short Physical Performance Battery (SPPB), physical disability by Health Assessment Questionnaire (HAQ), and physical activity by International Physical Activity Questionnaire (IPAQ). Paired t-tests, Pearson and Spearman correlations analyses, and multiple linear regression were conducted (p≤0.05).</p><p><strong>Result: </strong>Among 155 RA patients (88.4% women), 106 completed the 1-year follow-up. The baseline mean age was 58.7±9.5 years, median disease duration was 11.0 (6.0-20.0) years, and mean DAS28-CRP was 3.02±1.29. At follow-up, women exhibited a 7% reduction in VL, 6% in RF, and 4% in VI pennation angles (p≤0.05). Men showed a 39% increase in RF and a 29% in VI muscle thickness (p≤0.05). In women, lower baseline DAS28-CRP and higher muscle strength were correlated with increased muscle thickness (p≤0.05), with DAS28-CRP identified as a predictor of changes in muscle thickness (β=-0.058; CI95%,-0.114 to -0.003).</p><p><strong>Conclusion: </strong>RA women exhibited a decrease in pennation angle, while men had an increase in muscle thickness over time. Disease activity was a significant predictor of these changes in women, underscoring MU's clinical utility.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"66 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13488837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书